The Patent Finder
PT

Plurogen Therapeutics, LLC

First filing 2008
OverviewNotableFeesChangesPatent listSources & methods

0 patents currently held, every record listed here

6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

This portfolio holds none of the 6 US patents in force on its record. from the record

Of the 6 now held by other companies, 5 name Medline Industries LP as their current owner, and 1 more name another party. Each row says which.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
none
Next term end

When these terms end

Each bar runs from grant to computed term end. 2014 to 2036.
US 8,871,248 Compositions for Treating Biofilms and Methods for Using Same Feb 19, 2028
US 9,283,278 Compositions for Treating Biofilms and Methods for Using Same Feb 19, 2028
US 9,603,966 Compositions for Treating Biofilms and Methods for Using Same Feb 19, 2028
US 9,884,136 Compositions for Treating Biofilms and Methods for Using Same Feb 19, 2028
US 8,980,243 Surface Active Agent Compositions and Methods for Enhancing Oxygenation, Reducing Bacteria and Improving Wound Healing at a Site of Treatment Jan 11, 2031
US 10,456,416 Compositions and Methods of Treating Microbes Jan 20, 2036
20192024202920342036
Every computed term in this portfolio is shown above.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
None of the currently held patents qualifies as notable.

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 17 later US patents, top 25% of utility patents granted in 2016 in our data. Protection runs to 2028.
Ends Feb 2028 · High confidence
Also notable
Renewed at every maintenance window since the 2015 grant; no more fees are due before its term ends in 2031.
Ends Jan 2031 · High confidence
Also notable
The newest of the three, granted 2019. It anchors the portfolio to 2036, later than anything else here.
Ends Jan 2036 · High confidence

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Also on record: 6 patents in force now held by others · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited